This data is for laboratory research purposes only. Not for human or animal consumption.
What is Epitalon?
Epitalon (also known as epithalon or epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland that has been studied for its potential effects on telomerase activity and cellular aging mechanisms. Research suggests it may influence pineal function and circadian-related biological processes in laboratory models.
Mechanism of Action
Epitalon is theorized to interact with telomerase enzyme systems and may stimulate telomerase activity in certain cell types. The proposed mechanism involves modulation of neuroendocrine signaling pathways, particularly those related to pineal gland function and melatonin production. Laboratory studies suggest it may influence the hypothalamic-pituitary-pineal axis, though human mechanism clarification remains limited.
Observed Laboratory Results
- In-vitro studies demonstrated potential telomerase activation in cultured cells, with reported increases in enzyme activity under specific laboratory conditions
- Animal model research indicated possible effects on circadian rhythm regulation and sleep-related parameters
- Preliminary data suggested potential antioxidant properties through modulation of reactive oxygen species (ROS) pathways in cellular models
Note: Limited peer-reviewed clinical data exists for epitalon. Most evidence derives from non-human studies or preliminary research. Further investigation is needed for clinical application understanding.
Regulatory Status Update (July 2026 PCAC Vote)
On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7-5 (1 abstention) to recommend Epitalon for inclusion on the Section 503A Bulk Drug Substances List for a proposed insomnia indication — overriding FDA staff scientists, who had recommended against listing all seven peptides reviewed that week. This is a nonbinding advisory recommendation only: Epitalon is not FDA-approved in the US and is not yet legally compoundable under 503A. The FDA must still accept the recommendation and complete formal notice-and-comment rulemaking, a process experts estimate could take 8-12 months, before any status change takes legal effect.